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Background
Mutations in BRAF V600E oncogene (BRAFMT) occurs in
8-15% of colorectal cancer (CRC) patients1. This mutation
constitutively activates MAPK signalling, resulting in a
proliferative and survival advantage for the tumour cells
and oncogenic BRAF status has been linked with poor
prognosis2. Despite introduction of the BRAFMT specific
inhibitor Vemurafenib in metastatic melanoma3, there is
no effective treatment strategy for BRAFMT CRC patients.
This study aimed to assess the effectiveness of Ganetespib
(HSP90 inhibitor), the multi-kinase inhibitor (CRAF/
VEGFR/PDGFR) Sorafenib and the BRAFMT inhibitor
Vemurafenib in BRAFMT CRC cell line models.
Methods
BRAF MT RKO F6-8 (MT/WT) and isogenic wild-type
T29 (null/WT) cell lines were used. MTT assays were
used to determine IC50 values. Protein expression was
determined by Western Blotting. Levels of apoptotic cells
were assessed by flow cytometry.
Results
The RKO BRAFMT cell line was equally sensitive to Sora-
fenib and Ganetespib compared to the isogenic BRAFWT
clone (IC50 1.4µM vs. 0.9 µM and 0.86 nM vs. 0.79nM
respectively). Vemurafenib treatment resulted in a strong
decrease in MAPK signalling and showed greater specifi-
city towards BRAFMT cells (IC50 of 2.4µM vs. 3.3 µM)
than BRAFWT cells in cell viability assay. Western blot-
ting showed that neither Sorafenib nor Ganetespib had an
observable effect in targeting mutant BRAF. Sorafenib did
have some effect at targeting downstream MAPK signal-
ling however Ganetespib had no observable effect on tar-
geting the MAPK pathway in BRAF mutant cell lines.
Vemurafenib targeted BRAF and downstream MEK activa-
tion in both mutant-type cell lines but not in the wild-type
cell lines. We also found that treatment with Vemurafenib
induced activation of the STAT3 survival pathway, high-
lighting a resistance pathway which may be activated in
response to treatment in BRAFMT cell lines.
Conclusions
Despite the number of compounds which can target
BRAFMT cell lines through inhibition of mutant BRAF
directly or indirectly through inhibition of other pathways,
our studies have shown that Vemurafenib is the most
effective treatment strategy in the cell line model tested.
Effects of Ganetespib or Sorafenib treatment did not dis-
play specificity towards BRAFMT cells alone nor an effect
on mutant BRAF. Vemurafenib has shown selectivity
towards BRAFMT cells in which a reduction in MAPK
signaling is achieved along with induction of apoptosis.
Evidence of the emergence of a potential resistance
mechanism via STAT3 following Vemurafenib treatment
was also found giving insight into the kinome reprogram-
ming event which takes place following treatment.
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